Qiagen N.V.
QGEN
Pozycja w akcjach
#2054
Qiagen N.V. provides sample to insight solutions that transform biological... Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Cena akcji
$48.85
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$10.07B
Zmiana (1 dzień)
4.96%
Zmiana (1 rok)
0.61%
Kraj
NL
Handel Qiagen N.V. (QGEN)
Kategoria
Healthcare
Przychody dla Qiagen N.V. (QGEN)
Przychody w Jun 2026 TTM: $2.10B
Według najnowszych raportów finansowych Qiagen N.V., obecny przychód firmy (TTM) wynosi $2.10B. W roku 2024 firma osiągnęła przychód w wysokości $1.98B wzrost w porównaniu do przychodu z roku 2023, który wynosił $1.97B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Qiagen N.V. od 2000 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $2.10B | 0.50% |
| 2025 | $2.09B | 5.65% |
| 2024 | $1.98B | 0.66% |
| 2023 | $1.97B | -8.23% |
| 2022 | $2.14B | -4.89% |
| 2021 | $2.25B | 20.39% |
| 2020 | $1.87B | 22.53% |
| 2019 | $1.53B | 1.64% |
| 2018 | $1.50B | 5.95% |
| 2017 | $1.42B | 5.95% |
| 2016 | $1.34B | 4.45% |
| 2015 | $1.28B | -4.74% |
| 2014 | $1.34B | 3.29% |
| 2013 | $1.30B | 3.79% |
| 2012 | $1.25B | 7.24% |
| 2011 | $1.17B | 7.57% |
| 2010 | $1.09B | 7.69% |
| 2009 | $1.01B | 13.09% |
| 2008 | $892.98M | 37.43% |
| 2007 | $649.77M | 39.50% |
| 2006 | $465.78M | 16.91% |
| 2005 | $398.40M | 4.67% |
| 2004 | $380.63M | 8.32% |
| 2003 | $351.40M | 17.68% |
| 2002 | $298.61M | 13.21% |
| 2001 | $263.77M | 29.28% |
| 2000 | $204.03M | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $46.34B | 2,106.09% |
US
|
|
| $25.11B | 1,095.36% |
US
|
|
| $2.71B | 28.89% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 250.99% |
US
|
